No Magic Bullet for Preventing Late-Life Dementia
MONDAY, Dec. 18, 2017 -- The evidence of benefit for different types of interventions to prevent late-life dementia is limited, according to four reviews published online Dec. 18 in the Annals of Internal Medicine.
Michelle Brasure, Ph.D., M.S.P.H., from the University of Minnesota in Minneapolis, and colleagues reviewed data from 32 trials to examine the effectiveness of physical activity interventions in slowing cognitive decline and delaying the onset of cognitive impairment and dementia. The researchers found that the evidence for all the interventions was insufficient regarding effects on dementia prevention. In a second review, Howard A. Fink, M.D., M.P.H., also from the University of Minnesota, and colleagues found that estrogen and estrogen-progestin increased the risk for dementia or a combined outcome of mild cognitive impairment (MCI) or dementia; high-dose raloxifene decreased MCI but not dementia risk; and anti-hypertensives, non-steroidal anti-inflammatory drugs, and statins did not impact dementia risk. The evidence did not support use of pharmacologic treatments for cognitive protection.
Mary Butler, Ph.D., also from the University of Minnesota, and colleagues reviewed the evidence relating to efficacy and harms of over-the-counter supplements. The researchers found that daily folic acid plus vitamin B12 was correlated with improvements in performance on some objectively measured memory tests, although the clinical significance was unclear. A fourth review, also by Butler and colleagues, found that the evidence relating to cognitive training for prevention of cognitive decline in healthy older adults was insufficient.
"All evidence indicates that there is no magic bullet," writes the author of an accompanying editorial. "Our National Academy of Medicine committee searched in vain for convincing evidence of effective preventive interventions."
Abstract/Full Text - Review 1 (subscription or payment may be required)
Abstract/Full Text - Review 2 (subscription or payment may be required)
Abstract/Full Text - Review 3 (subscription or payment may be required)
Abstract/Full Text - Review 4 (subscription or payment may be required)
Editorial (subscription or payment may be required)
© 2020 HealthDay. All rights reserved.
Posted: December 2017
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.